Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 455
Filter
Add filters

Document Type
Year range
2.
Curr Oncol Rep ; 23(11): 134, 2021 10 22.
Article in English | MEDLINE | ID: covidwho-1530397

ABSTRACT

PURPOSE OF REVIEW: Since the past year, the fast spread of coronavirus disease 2019 (COVID-19) has represented a global health threat, especially for cancer patients, that has required an urgent reorganization of clinical activities. Here, we will critically revise the profound impact that the pandemic has generated in lung cancer patients, as well the most significant challenges that oncologists have to face to maintain the highest possible standards in the management of lung cancer patients in the pandemic era. RECENT FINDINGS: Evidences suggested a higher susceptibility and mortality of lung cancer patients due to COVID-19. The hard management of this patient population has been also due to the potential cross interference of anti-tumor drugs on SARS-Cov-2 infection and to the differential diagnosis between COVID-19 pneumonitis and drug-related pneumonitis. COVID-19 pandemic has generated a profound reshaping of oncological activities and the development of recommendations by the oncology scientific community to prioritize anti-tumor treatments for lung cancer patients.


Subject(s)
COVID-19/complications , COVID-19/mortality , Lung Neoplasms/complications , Lung Neoplasms/mortality , Pneumonia/diagnosis , Antineoplastic Agents/pharmacology , COVID-19 Vaccines , Comorbidity , Diagnosis, Differential , Humans , Medical Oncology/methods , Pandemics , Risk Factors , SARS-CoV-2 , Tomography, X-Ray Computed
3.
Curr Oncol ; 28(6): 4774-4775, 2021 11 17.
Article in English | MEDLINE | ID: covidwho-1523893

ABSTRACT

Prior to the COVID-19 pandemic, the Canadian Cancer Society had already projected added pressures on cancer care services, predicting an increase of 79% in cancer cases by 2028-2032 [...].


Subject(s)
COVID-19 , Pandemics , Canada , Humans , Medical Oncology , SARS-CoV-2
5.
Lancet Oncol ; 22(11): 1499-1500, 2021 11.
Article in English | MEDLINE | ID: covidwho-1492831
6.
Nat Rev Clin Oncol ; 18(11): 675, 2021 11.
Article in English | MEDLINE | ID: covidwho-1488032
7.
Lancet Oncol ; 22(11): e474-e487, 2021 11.
Article in English | MEDLINE | ID: covidwho-1488012

ABSTRACT

The increasing burden of cancer represents a substantial problem for Latin America and the Caribbean. Two Lancet Oncology Commissions in 2013 and 2015 highlighted potential interventions that could advance cancer care in the region by overcoming existing challenges. Areas requiring improvement included insufficient investment in cancer control, non-universal health coverage, fragmented health systems, inequitable concentration of cancer services, inadequate registries, delays in diagnosis or treatment initiation, and insufficient palliative services. Progress has been made in key areas but remains uneven across the region. An unforeseen challenge, the COVID-19 pandemic, strained all resources, and its negative effect on cancer control is expected to continue for years. In this Series paper, we summarise progress in several aspects of cancer control since 2015, and identify persistent barriers requiring commitment of additional resources to reduce the cancer burden in Latin America and the Caribbean.


Subject(s)
COVID-19/epidemiology , Neoplasms/prevention & control , SARS-CoV-2 , Caribbean Region/epidemiology , Cost of Illness , Delivery of Health Care/economics , Early Detection of Cancer , Health Services Accessibility , Humans , Latin America/epidemiology , Medical Oncology/education , Neoplasms/epidemiology
8.
Oncology (Williston Park) ; 35(1): 26-28, 2021 Jan 11.
Article in English | MEDLINE | ID: covidwho-1485807

ABSTRACT

Against the difficult and trying backdrop of the pandemic, cancer investigators persisted, and for patients with lung cancer, that persistence paid off in spectacular ways. With several new FDA approved treatments, as well as 2 new targetable mutations in non-small cell lung cancer (NSCLC), 2020 was a banner year in the overall lung cancer space. ONCOLOGY® recently sat down with Jennifer W. Carlisle, MD, of Emory University's Winship Cancer Institute, to discuss the many advances made during the last year for patients with lung cancer along with her hopes for further significant milestones in the year to come.


Subject(s)
COVID-19/epidemiology , Lung Neoplasms/drug therapy , Medical Oncology/organization & administration , Antineoplastic Agents, Immunological/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Humans , Lung Neoplasms/genetics , Precision Medicine , SARS-CoV-2
9.
Technol Cancer Res Treat ; 20: 15330338211035037, 2021.
Article in English | MEDLINE | ID: covidwho-1484272

ABSTRACT

BACKGROUND: Oncotype Dx (ODx) is a genomic assay which estimates the risk of distant recurrence and predicts adjuvant chemotherapy benefit in early stage breast cancer patients. Most ODx data is derived from excisional specimens. AIM: We assess the utility of ODx on core needle biopsies (CNB) and measure its impact on neoadjuvant treatment decisions, particularly in patients with clinically complicated situations. METHODS: Consecutive ODx results on breast CNBs with invasive carcinoma from 2012-2020 at 3 tertiary care hospitals with dedicated Breast Health Centers were reviewed. Clinical indications to perform ODx on CNB were recorded through a review of patients' electronic medical records. Clinicopathologic features, surgical or oncologic modalities and follow-up data were recorded. RESULTS: Three distinct clinical indications for performing ODx on CNB in 85 ER+ invasive breast carcinomas were identified: 1) Excisions with insufficient tissue to perform ODx, 2) adjudicate neoadjuvant therapy versus primary surgical resection, and 3) select neoadjuvant chemotherapy (NAC) versus neoadjuvant endocrine therapy (NET). Primary surgery was selected in patients with low score RS (<18), and NET was preferred in patients with intermediate or high RS (>18). NET was preferred over NAC in patients with low RS (<18). CONCLUSION: This study shows that CNB ODx RS helps guide treatment decisions in a neoadjuvant setting along with other contributing factors such as the presence of pathogenic mutations, node positivity, patient age, and comorbidities. The use of ODx on CNB is furthermore valuable in the midst of the COVID-19 pandemic for early breast cancer patients to administer effective therapy in a timely manner.


Subject(s)
Breast Neoplasms, Male/diagnosis , Breast Neoplasms/diagnosis , Carcinoma, Ductal, Breast/diagnosis , Neoplasm Recurrence, Local , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Biopsy, Large-Core Needle , Breast Neoplasms/pathology , Breast Neoplasms, Male/pathology , Carcinoma , Carcinoma, Ductal, Breast/pathology , Combined Modality Therapy , Electronic Health Records , Female , Gene Expression Profiling/methods , Genomics , Hormones/therapeutic use , Humans , Male , Medical Oncology , Middle Aged , Neoadjuvant Therapy , Neoplasm Invasiveness , Retrospective Studies , Treatment Outcome
10.
Technol Cancer Res Treat ; 20: 15330338211050764, 2021.
Article in English | MEDLINE | ID: covidwho-1477207

ABSTRACT

A pandemic of coronavirus diseases 2019 (COVID-19) outbreak is a major public health emergency that has spread in the fastest speed, and caused the most extensive infection world widely. Transbronchial biopsy (TBB) and computed tomography guided percutaneous needle biopsy (CTPNB) is the most common and significant method for the diagnosis of lung cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB must be managed strictly. Therefore, it is extremely indispensable to perform meticulous and individualized management for lung cancer patients to protect the patients from COVID-19.


Subject(s)
COVID-19/epidemiology , Lung Neoplasms/diagnosis , Biopsy , Bronchi/pathology , Bronchoscopy/methods , COVID-19/complications , COVID-19/diagnosis , Diagnosis, Differential , Disease Susceptibility , Humans , Image-Guided Biopsy/methods , Lung/pathology , Lung Neoplasms/complications , Medical Oncology/methods , Postoperative Period , Prognosis , SARS-CoV-2 , Telemedicine , Tomography, X-Ray Computed
11.
ESMO Open ; 6(4): 100199, 2021 08.
Article in English | MEDLINE | ID: covidwho-1466337

ABSTRACT

BACKGROUND: The COVID-19 pandemic has resulted in significant changes to professional and personal lives of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration aimed to provide contemporaneous reports on the impact of COVID-19 on the lived experiences and well-being in oncology. METHODS: This online anonymous survey (July-August 2020) is the second of a series of global surveys launched during the course of the pandemic. Longitudinal key outcome measures including well-being/distress (expanded Well-being Index-9 items), burnout (1 item from expanded Well-being Index), and job performance since COVID-19 were tracked. RESULTS: A total of 942 participants from 99 countries were included for final analysis: 58% (n = 544) from Europe, 52% (n = 485) female, 43% (n = 409) ≤40 years old, and 36% (n = 343) of non-white ethnicity. In July/August 2020, 60% (n = 525) continued to report a change in professional duties compared with the pre-COVID-19 era. The proportion of participants at risk of poor well-being (33%, n = 310) and who reported feeling burnout (49%, n = 460) had increased significantly compared with April/May 2020 (25% and 38%, respectively; P < 0.001), despite improved job performance since COVID-19 (34% versus 51%; P < 0.001). Of those who had been tested for COVID-19, 8% (n = 39/484) tested positive; 18% (n = 7/39) felt they had not been given adequate time to recover before return to work. Since the pandemic, 39% (n = 353/908) had expressed concerns that COVID-19 would have a negative impact on their career development or training and 40% (n = 366/917) felt that their job security had been compromised. More than two-thirds (n = 608/879) revealed that COVID-19 has changed their outlook on their work-personal life balance. CONCLUSION: The COVID-19 pandemic continues to impact the well-being of oncology professionals globally, with significantly more in distress and feeling burnout compared with the first wave. Collective efforts from both national and international communities addressing support and coping strategies will be crucial as we recover from the COVID-19 crisis. In particular, an action plan should also be devised to tackle concerns raised regarding the negative impact of COVID-19 on career development, training, and job security.


Subject(s)
Burnout, Professional , COVID-19 , Adult , Burnout, Professional/epidemiology , Female , Humans , Medical Oncology , Pandemics , SARS-CoV-2
12.
Clin J Oncol Nurs ; 25(5): 495, 2021 10 01.
Article in English | MEDLINE | ID: covidwho-1468121

ABSTRACT

This past summer, three pivotal trend reports were released that give direction to clinical oncology care and oncology nursing. After a tumultuous 2020, results from the 2020 U.S. census were finally compiled and reported in August 2021.


Subject(s)
Medical Oncology , Oncology Nursing , Humans
17.
Repert. med. cir ; 29((Núm. Supl.1.)): 22-26, 2020.
Article in English, Spanish | LILACS (Americas) | ID: covidwho-1436548

ABSTRACT

El mundo vive una pandemia por un Coronavirus, llamado SARS-COV-2, que produce la COVID-19 (acrónimo del ingles coronavirus disease 2019), la cual ha generado un colapso en los sistemas de salud, haciendo que el manejo de otras enfermedades se convierta en un reto. De igual forma para los grupos oncológicos, la presencia de esta enfermedad, genera muchas dudas en la aplicación de los tratamientos estándares, los cuales se deben realizar lo antes posible, con el fin de ofrecer mejores resultados oncológicos. Se propone la creación de un índice ( COVID-19 Cáncer Index) , teniendo en cuenta variables clínicas, epidemiológicas y la disponibilidad de los recursos hospitalarios, útil para la toma de decisiones y el establecimiento del mejor tratamiento para una paciente con confirmación o alta sospecha de neoplasia ginecológica.


The world is experiencing a coronavirus pandemic called SARS-COV-2 which causes coronavirus disease 2019 (COVID 19). This has led to a collapse in health systems, making the management of other diseases a challenge. Similarly, the presence of this disease generates many doubts for oncological groups regarding the provision of standard treatments, which should be carried out as soon as possible, in order to ensure better oncological outcomes. We propose the creation of an index (COVID 19 Cancer Index) taking into account clinical and epidemiological variables and the availability of hospital resources, which are useful for decision making and determining the best treatment for a patient with confirmed or strongly suspected gynecological neoplasia.


Subject(s)
Humans , Coronavirus Infections , Genital Neoplasms, Female , Pandemics , Medical Oncology , Neoplasms
20.
Curr Treat Options Oncol ; 22(10): 95, 2021 09 13.
Article in English | MEDLINE | ID: covidwho-1404665

ABSTRACT

OPINION STATEMENT: While emergency use is authorized for numerous COVID-19 vaccines and the high-risk population including cancer patients or those with immunosuppression due to disease or therapy is prioritized, data on this group's specific safety and efficacy of these vaccines remains limited. Safety data from clinical trials and population data may be extrapolated, and these vaccines may be used for cancer patients. However, concerns of efficacy due to the variable immune response in patients with active cancers undergoing active therapy and cancer survivors with chronic immunosuppression remain. The authors aim to discuss the current recommendations for use of COVID-19 vaccination in patients with cancer.


Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19 Vaccines/therapeutic use , COVID-19/prevention & control , Neoplasms/immunology , Vaccination/adverse effects , COVID-19/complications , Humans , Immune System , Immunization , Immunocompromised Host , Medical Oncology/standards , Neoplasms/complications , Patient Safety , Practice Guidelines as Topic , SARS-CoV-2 , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...